CN112533675A - 通过递送抗OSMRβ抗体治疗皮肤疾病或病症 - Google Patents

通过递送抗OSMRβ抗体治疗皮肤疾病或病症 Download PDF

Info

Publication number
CN112533675A
CN112533675A CN201980039355.2A CN201980039355A CN112533675A CN 112533675 A CN112533675 A CN 112533675A CN 201980039355 A CN201980039355 A CN 201980039355A CN 112533675 A CN112533675 A CN 112533675A
Authority
CN
China
Prior art keywords
subject
osmr
dose
pruritus
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980039355.2A
Other languages
English (en)
Chinese (zh)
Inventor
J.帕奥里尼
R.甘迪
Z.米克哈克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kiniksa Phamaceuticals Ltd
Original Assignee
Kiniksa Phamaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kiniksa Phamaceuticals Ltd filed Critical Kiniksa Phamaceuticals Ltd
Priority to CN202510495862.4A priority Critical patent/CN121818914A/zh
Publication of CN112533675A publication Critical patent/CN112533675A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980039355.2A 2018-04-25 2019-04-25 通过递送抗OSMRβ抗体治疗皮肤疾病或病症 Pending CN112533675A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510495862.4A CN121818914A (zh) 2018-04-25 2019-04-25 通过递送抗OSMRβ抗体治疗皮肤疾病或病症

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US201862662607P 2018-04-25 2018-04-25
US62/662,607 2018-04-25
US201862718324P 2018-08-13 2018-08-13
US62/718,324 2018-08-13
US201862765033P 2018-08-16 2018-08-16
US62/765,033 2018-08-16
US201862731618P 2018-09-14 2018-09-14
US62/731,618 2018-09-14
US201862757047P 2018-11-07 2018-11-07
US62/757,047 2018-11-07
US201862775350P 2018-12-04 2018-12-04
US62/775,350 2018-12-04
US201962789434P 2019-01-07 2019-01-07
US62/789,434 2019-01-07
US201962794356P 2019-01-18 2019-01-18
US62/794,356 2019-01-18
PCT/IB2019/000619 WO2019229525A2 (en) 2018-04-25 2019-04-25 TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRβ ANTIBODY

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510495862.4A Division CN121818914A (zh) 2018-04-25 2019-04-25 通过递送抗OSMRβ抗体治疗皮肤疾病或病症

Publications (1)

Publication Number Publication Date
CN112533675A true CN112533675A (zh) 2021-03-19

Family

ID=68234020

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980039355.2A Pending CN112533675A (zh) 2018-04-25 2019-04-25 通过递送抗OSMRβ抗体治疗皮肤疾病或病症
CN202510495862.4A Pending CN121818914A (zh) 2018-04-25 2019-04-25 通过递送抗OSMRβ抗体治疗皮肤疾病或病症

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510495862.4A Pending CN121818914A (zh) 2018-04-25 2019-04-25 通过递送抗OSMRβ抗体治疗皮肤疾病或病症

Country Status (12)

Country Link
US (3) US20210054085A1 (enExample)
EP (1) EP3784347A2 (enExample)
JP (2) JP2021522241A (enExample)
KR (2) KR102849806B1 (enExample)
CN (2) CN112533675A (enExample)
AU (2) AU2019276779A1 (enExample)
BR (1) BR112020021739A2 (enExample)
CA (1) CA3096582A1 (enExample)
IL (1) IL326629A (enExample)
MX (2) MX2020011172A (enExample)
SG (1) SG11202010034WA (enExample)
WO (1) WO2019229525A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI871349B (zh) * 2020-09-01 2025-02-01 日商中外製藥股份有限公司 含有il-31拮抗劑作為有效成分之透析搔癢症的預防用及/或治療用醫藥組合物
CA3189847A1 (en) * 2020-09-01 2022-03-10 Naoki Fukazawa Pharmaceutical composition for prevention and/or treatment of dialysis pruritus containing il-31 antagonist as active ingredient
TW202607038A (zh) 2020-10-19 2026-02-16 美商碩騰服務公司 犬及貓抑瘤素Ｍ受體β之抗體及其用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060188499A1 (en) * 2005-02-14 2006-08-24 Leung Donald Y Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells
AU2012202218A1 (en) * 2005-02-14 2012-05-10 National Jewish Medical And Research Center Methods Of Treating Diseases Which Are Mediated By Cutaneous Lymphocyte Antigen Positive Cells
WO2013168829A1 (en) * 2012-05-11 2013-11-14 Wakayama Medical University Anti oncostatin m receptor beta antibody
CN105377894A (zh) * 2013-06-04 2016-03-02 瑞泽恩制药公司 以il-4r抑制剂治疗过敏症及强化过敏原特异性免疫治疗的方法
US20160137739A1 (en) * 2013-05-30 2016-05-19 Biogen Ma Inc. Oncostatin m receptor antigen binding proteins
AU2016210996A1 (en) * 2015-01-29 2017-08-17 Oxford University Innovation Limited Therapeutic target and biomarker in IBD
AU2016248786A1 (en) * 2015-04-14 2017-10-26 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing lL-31 antagonist as active ingredient

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060188499A1 (en) * 2005-02-14 2006-08-24 Leung Donald Y Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells
AU2012202218A1 (en) * 2005-02-14 2012-05-10 National Jewish Medical And Research Center Methods Of Treating Diseases Which Are Mediated By Cutaneous Lymphocyte Antigen Positive Cells
WO2013168829A1 (en) * 2012-05-11 2013-11-14 Wakayama Medical University Anti oncostatin m receptor beta antibody
US20160137739A1 (en) * 2013-05-30 2016-05-19 Biogen Ma Inc. Oncostatin m receptor antigen binding proteins
CN107513105A (zh) * 2013-05-30 2017-12-26 基尼克萨制药有限公司 制瘤素m受体抗原结合蛋白
CN105377894A (zh) * 2013-06-04 2016-03-02 瑞泽恩制药公司 以il-4r抑制剂治疗过敏症及强化过敏原特异性免疫治疗的方法
AU2016210996A1 (en) * 2015-01-29 2017-08-17 Oxford University Innovation Limited Therapeutic target and biomarker in IBD
AU2016248786A1 (en) * 2015-04-14 2017-10-26 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing lL-31 antagonist as active ingredient

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JUSTYNA A KUCIA-TRAN: "Anti-oncostatin M antibody inhibits the pro-malignant effects of oncostatin M receptor overexpression in squamous cell carcinoma", 《THE JOURNAL OF PATHOLOGY 》, vol. 244, no. 3, pages 283 - 295 *
戴体俊: "《麻醉药理学进展 2012年》", 31 July 2012, 第二军医大学出版社, pages: 126 *

Also Published As

Publication number Publication date
AU2026201985A1 (en) 2026-04-02
US20210054085A1 (en) 2021-02-25
CN121818914A (zh) 2026-04-10
WO2019229525A2 (en) 2019-12-05
JP2024096933A (ja) 2024-07-17
KR20210018808A (ko) 2021-02-18
AU2019276779A1 (en) 2020-12-10
EP3784347A2 (en) 2021-03-03
MX2020011172A (es) 2021-01-29
US20240101690A1 (en) 2024-03-28
SG11202010034WA (en) 2020-11-27
JP2021522241A (ja) 2021-08-30
WO2019229525A3 (en) 2020-03-19
KR20250127348A (ko) 2025-08-26
MX2025006542A (es) 2025-07-01
BR112020021739A2 (pt) 2021-01-26
KR102849806B1 (ko) 2025-08-22
IL326629A (en) 2026-04-01
CA3096582A1 (en) 2019-12-05
US20250236676A1 (en) 2025-07-24

Similar Documents

Publication Publication Date Title
US20230312594A1 (en) PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
Hoffman et al. Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study
TWI837532B (zh) 治療潰瘍性結腸炎之方法
US11512092B2 (en) Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Quinteiro et al. 15-deoxy-Δ12, 14-prostaglandin J2 reduces albumin-induced arthritis in temporomandibular joint of rats
US11524964B2 (en) Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US20250236676A1 (en) TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRBeta ANTIBODY
Vitiello et al. An update on the treatment of the cutaneous manifestations of systemic sclerosis: the dermatologist's point of view
KR20210145295A (ko) Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물
US11780848B2 (en) Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
CN118178647A (zh) 用于治疗类风湿性关节炎或作为镇痛药的中和gm-csf的抗体
CN113453759A (zh) 治疗巨细胞动脉炎
WO2017125502A1 (en) Substance that inhibits p2y12 receptor, for use in the preventive treatment of systemic sclerosis in patients with raynaud's phenomenon and a dysimmunity
Cooke et al. Raynaud's syndrome
TWI856006B (zh) 具有中至重度表皮脫落之異位性皮膚炎之治療
US20250250277A1 (en) PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
JP2022502441A (ja) Ｃｃｒ３阻害剤を用いて、加齢性機能障害を治療するための方法および組成物
BR122025027043A2 (pt) USO DE ANTICORPO ANTI-OSMRbeta
EP3952993B1 (en) Method of treating fumaric acid ester-resistant plaque psoriasis
Golant et al. Psoriasis Treatments: A review of the current research pipeline
CN107106583B (zh) 包含阿卡波糖之医药组合物及其用于免疫调节之用途
Becker et al. Pediatric Psoriasis
Bonifazi What's new in Pediatric Dermatology
鎌谷宇明 et al. Oral lichenoid drug eruption induced by ethambutol (Esanbutol): A case report
TW201642871A (zh) 包含阿卡波糖之醫藥組合物及其用於免疫調節之用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20210319